IL2 and acute myeloid leukemia: The first-in-human trial of using in vivo recombinant human IL-15 to potentiate haploidentical NK cell transfer in R/R AML showed better rates of NK cell expansion and remission compared with previous trials with IL-2, but CRS was observed when IL-15 was administered subcutaneously [106].